Y-mAbs Therapeutics (NASDAQ:YMAB) Announces Earnings Results, Misses Expectations By $0.05 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) announced its earnings results on Wednesday. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05), Fidelity Earnings reports.

YMAB stock opened at $26.45 on Friday. The company has a market capitalization of $882.88 million and a PE ratio of -17.63. Y-mAbs Therapeutics has a one year low of $15.17 and a one year high of $31.00. The company’s 50 day moving average price is $23.04 and its two-hundred day moving average price is $22.74. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.30 and a current ratio of 13.30.

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $21.78, for a total transaction of $87,120.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 30,000 shares of company stock worth $646,500 over the last three months. Insiders own 38.40% of the company’s stock.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Y-mAbs Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Saturday, August 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price (up from $36.00) on shares of Y-mAbs Therapeutics in a research note on Monday, June 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Monday, July 1st. Six equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $31.40.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Further Reading: What are the advantages of the Stochastic Momentum Index?

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.